Xiangu Chen | Biomedical and Healthcare Applications | Best Research Article Award

Published on by Computer Vision Awards

Prof. Xianguo Chen | Biomedical and Healthcare Applications | Best Research Article Award

Professor | Zhejiang University School of Medicine | China

Dr. Xianguo Chen is an active researcher in the field of lung cancer biology, molecular oncology, and precision medicine, with a strong focus on exploring genetic alterations, therapeutic resistance mechanisms, and biomarker-driven clinical translation. Affiliated with the Zhejiang University School of Medicine, Dr. Chen has established a robust research portfolio, contributing 16 scientific publications, accumulating 48 citations, and maintaining an h-index of 4, reflecting consistent scholarly impact within a rapidly evolving biomedical landscape.Dr. Chen’s research spans critical areas of lung adenocarcinoma, non-small cell lung cancer (NSCLC), oncogenic signaling pathways, and clinical molecular diagnostics. His work includes multiple contributions as first author, corresponding author, and co-corresponding author, demonstrating scientific leadership and collaboration across multidisciplinary teams. Notable publications include studies on miR-1293–mediated angiogenesis regulation, carbonic anhydrase 4 as a prognostic biomarker, and the identification of novel RET and ALK fusions in NSCLC, each contributing valuable insights into cancer progression, heterogeneity, and precision-targeted therapy.His commitment to translational oncology is further reflected in several research grants. These include major funded projects focused on acacetin-mediated SMYD2 inhibition and DNA damage repair, KMT3C-driven osimertinib resistance via ENO1-regulated glycolysis, and metabolomic discrimination of pulmonary nodules combined with fecal microbiota transplantation strategies. These funded studies highlight his expertise in integrating molecular biology, bioinformatics, and therapeutic research to address pressing clinical challenges in cancer diagnosis and treatment.In addition to his publication record, Dr. Chen engages in collaborative research involving over 130 co-authors, demonstrating broad interdisciplinary partnerships across medical, molecular, and computational sciences. His recent article on machine learning–based immune prognosis modeling for lung adenocarcinoma extends his contributions into the domain of AI-assisted oncology, reinforcing the relevance of computational technologies in modern cancer research.Dr. Chen’s scientific efforts collectively aim to enhance early cancer detection, refine prognostic tools, and illuminate new molecular targets for therapy. Through his funded projects, high-quality publications, and sustained collaborative activity, he continues to contribute significantly to the advancement of global lung cancer research and its transition toward more personalized, mechanism-driven clinical care.

Profiles: Scopus | ResearchGate

Featured Publication

1.Construction and validation of immune prognosis model for lung adenocarcinoma based on machine learning. (2025). Frontiers in Oncology.

Dr. Xianguo Chen research advances precision oncology by uncovering molecular mechanisms that drive lung cancer progression and therapeutic resistance, enabling more accurate diagnostics and targeted treatment strategies.

Shenglin Wang | Biomedical and Healthcare Applications | Young Scientist Award

Published on by Computer Vision Awards

Dr. Shenglin Wang | Biomedical and Healthcare Applications | Young Scientist Award

Clinician-Scientist | Fujian Medical University | China

Dr. Shenglin Wang is a biomedical researcher whose work focuses on tumor biology, cancer metastasis, and molecular mechanisms underlying osteosarcoma, chondrosarcoma, and lung cancer bone lesions. He completed a Post-doctoral Fellowship at Fujian Medical University where he advanced single-cell sequencing, tumor microenvironment profiling, and molecular pathology research. In 2025, he joined The First Affiliated Hospital of Fujian Medical University as a Physician, continuing to integrate clinical oncology with translational cancer research.Over the last five years, Dr. Wang has secured three competitive research grants as Principal Investigator or Co-Investigator. His ongoing NSFC project  investigates SOX18-mediated endothelial senescence and HBEGF secretion in non-small cell lung cancer bone metastasis, aiming to define novel therapeutic targets within the senescent vascular niche. He also leads a provincial project exploring HMGA2-regulated ferroptosis resistance in chondrosarcoma, contributing to the understanding of tumor progression and cell death mechanisms. His completed NSFC project, focused on aptamer-based electrochemical sensing for rapid detection of circulating tumor cells, reflects his multidisciplinary approach combining bioengineering with oncology.Dr. Wang has authored 33 peer-reviewed publications, accumulating 651 citations, with an h-index of 11, demonstrating sustained research productivity and academic impact. His representative articles include studies in Cell Proliferation, Frontiers in Immunology, and Acta Biochimica et Biophysica Sinica, covering topics such as single-cell transcriptomics of metastatic bone microenvironments, immune regulatory networks in thyroid carcinoma, and STAT3/EGFR signaling in osteosarcoma drug resistance. His collaborative work spans more than 60 co-authors, highlighting strong interdisciplinary engagement.Collectively, Dr. Wang’s research advances understanding of tumor microenvironment remodeling, therapeutic resistance, and metastasis-associated cell senescence. His contributions support the development of precision oncology strategies and have broad implications for improving diagnostic, prognostic, and therapeutic outcomes in bone-related malignancies.

Profiles:  Scopus | ResearchGate

Featured Publications

1. Author(s). (2025). The integrin α2–osteoclast axis: A key driver of bone destruction and therapeutic target in osteosarcoma. Journal of Translational Medicine.

2. Author(s). (2021). Corrigendum: Stattic sensitizes osteosarcoma cells to epidermal growth factor receptor inhibitors via blocking the interleukin 6-induced STAT3 pathway. Acta Biochimica et Biophysica Sinica, 53(12), 1670–1680.

3. Author(s). (2025). Single-cell transcriptomic analysis of the senescent microenvironment in bone metastasis. Cell Proliferation, 58(1), e13743. Cited By : 5

The nominee’s work advances precision oncology by uncovering key molecular and microenvironmental mechanisms that drive tumor progression, therapeutic resistance, and bone metastasis, enabling the development of more effective diagnostic and therapeutic strategies. By integrating single-cell analytics, molecular signaling research, and translational innovation, the nominee contributes to improved cancer outcomes and supports global efforts toward personalized, mechanism-driven cancer care.